RELATIVITY098
09 May 2022
Trial Summary
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
Acronym:
RELATIVITY098
ACTRN/NCT /ethics:
NCT05002569
Scientific title:
A Study to Assess Adjuvant Immunotherapy With Relatlimab and Nivolumab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)
Sponsor / Cooperative group:
Bristol-Myers Squibb
Trial & Patient Characteristics
| Cancer Type | Melanoma & other skin |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2021-10-19 |
| Anticipated End Date | 2025-12-15 |
Participating Hospitals
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Stella Papacharissiou |
| stella.papacharissiou@sa.gov.au | |
| Phone | 08 8222 6140 |
| Principal Investigator | Dr Rachel Roberts-Thomson |
| Recruitment Status | Not Yet Recruiting |